Brokerages Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Target Price at $336.30

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has been given a consensus rating of “Buy” by the nine ratings firms that are covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $336.30.

Several equities research analysts have commented on ONC shares. Barclays started coverage on BeOne Medicines in a research note on Thursday, September 18th. They set an “overweight” rating and a $385.00 price objective for the company. Wall Street Zen cut shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 5th. Zacks Research upgraded shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 18th. Royal Bank Of Canada increased their target price on shares of BeOne Medicines from $349.00 to $364.00 and gave the company an “outperform” rating in a research report on Thursday, August 7th. Finally, JPMorgan Chase & Co. increased their target price on shares of BeOne Medicines from $321.00 to $345.00 and gave the company an “overweight” rating in a research report on Thursday, July 17th.

Insiders Place Their Bets

In other news, insider Lai Wang sold 5,000 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $350.06, for a total value of $1,750,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $337.00, for a total transaction of $898,105.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 181,315 shares of company stock valued at $54,839,498. Corporate insiders own 6.62% of the company’s stock.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently bought and sold shares of ONC. Primecap Management Co. CA acquired a new stake in BeOne Medicines during the second quarter worth about $1,231,720,000. Temasek Holdings Private Ltd acquired a new stake in BeOne Medicines during the second quarter worth about $244,603,000. Marshall Wace LLP acquired a new stake in BeOne Medicines during the second quarter worth about $113,190,000. Baird Financial Group Inc. acquired a new stake in shares of BeOne Medicines during the second quarter valued at about $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of BeOne Medicines during the second quarter valued at about $73,347,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeOne Medicines Stock Down 2.6%

Shares of NASDAQ ONC opened at $329.07 on Friday. BeOne Medicines has a 52-week low of $170.99 and a 52-week high of $351.27. The company’s 50-day simple moving average is $311.61 and its 200-day simple moving average is $269.38. The company has a quick ratio of 1.72, a current ratio of 1.95 and a debt-to-equity ratio of 0.04. The firm has a market cap of $36.09 billion, a price-to-earnings ratio of -190.21 and a beta of 0.21.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, topping the consensus estimate of $0.48 by $0.36. BeOne Medicines had a negative return on equity of 1.22% and a negative net margin of 3.89%.The company had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.24 billion. Equities analysts predict that BeOne Medicines will post -5.82 EPS for the current fiscal year.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.